SCHEMBL3278742

SCHEMBL3278742

OC1CCC2CCCN1C2

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.45
MAN2B1 O00754 1/20 0.39
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6152816 0.85
Hydrochloric Acid SCHEMBL30922986 0.83 SLC18A3 (0.41) SLC18A3
SCHEMBL11350359 0.81
SCHEMBL15865508 0.71 SLC18A3 (0.35) SLC18A3MAN2B1ALDH1A1
SCHEMBL701424 0.71 SLC18A3 (0.35) SLC18A3MAN2B1ALDH1A1
SCHEMBL2336833 0.67
SCHEMBL11086482 0.64 SLC18A3 (0.38) SLC18A3ALDH1A1
SCHEMBL27729 0.62
SCHEMBL31589383 0.60
SCHEMBL16570976 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458522-B1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM SPA (IT) 2024-01-03 EP claimed
US-10723710-B2 Process for the preparation of diaminophenothiazinium compounds having a high degree of purity ICROM S.P.A. (IT) 2020-07-28 US claimed
US-20190185440-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM S.P.A. (IT) 2019-06-20 US claimed
US-9856364-B2 Stabilized reversible polymer composition XEROX CORPORATION (US) 2018-01-02 US claimed
US-20140353549-A1 STABILIZED REVERSIBLE POLYMER COMPOSITION XEROX CORPORATION (US) 2014-12-04 US claimed
EP-0717054-A2 Stable free radical polymerization process and thermoplastic materials produced therefrom XEROX CORPORATION (US) 1996-06-19 EP claimed
US-5449724-A Stable free radical polymerization process and thermoplastic materials produced therefrom XEROX CORPORATION (US) 1995-09-12 US claimed
EP-3458522-B1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM SPA (IT) 2024-01-03 EP disclosed
US-10723710-B2 Process for the preparation of diaminophenothiazinium compounds having a high degree of purity ICROM S.P.A. (IT) 2020-07-28 US disclosed
US-20190185440-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY ICROM S.P.A. (IT) 2019-06-20 US disclosed
US-9856364-B2 Stabilized reversible polymer composition XEROX CORPORATION (US) 2018-01-02 US disclosed
US-20150337147-A1 REVERSIBLE POLYMERS IN 3-D PRINTING XEROX CORPORATION (US) 2015-11-26 US disclosed
US-9193139-B2 Reversible polymer adhesive composition XEROX CORPORATION (US) 2015-11-24 US disclosed
WO-2004101562-A2 BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS SCHERING CORPORATION (US) 2004-11-25 WO disclosed
US-20040229902-A1 Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors SCHERING CORPORATION 2004-11-18 US disclosed
US-6156858-A Stable free radical polymerization processes XEROX CORPORATION (US) 2000-12-05 US disclosed
EP-0780733-A1 Polymerization multiblock copolymer process and compositions thereof XEROX CORPORATION (US) 1997-06-25 EP disclosed
US-5552502-A Polymerization process and compositions thereof XEROX CORPORATION (US) 1996-09-03 US disclosed
EP-0717054-A2 Stable free radical polymerization process and thermoplastic materials produced therefrom XEROX CORPORATION (US) 1996-06-19 EP disclosed
US-5449724-A Stable free radical polymerization process and thermoplastic materials produced therefrom XEROX CORPORATION (US) 1995-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723710-B2 Process for the preparation of diaminophenothiazinium compounds having a high degree of purity DDT, QDPR, DDC SLC18A3 2819/4885MAN2B1 1985/4885TDP1 1351/4885
US-20190185440-A1 PROCESS FOR THE PREPARATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS HAVING A HIGH DEGREE OF PURITY DDT, QDPR, DDC SLC18A3 2819/4885MAN2B1 1985/4885TDP1 1351/4885
US-20040229902-A1 Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors BACE1, BACE2, PSEN1 SLC18A3 3598/4885MAN2B1 558/4885TDP1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.